Scared to death-A novel mutation in catecholaminergic polymorphic ventricular tachycardia.
作者信息
Jain Nikhil, Holbert Jaime C, Black William, Hussein Reem, Baljepally Gayathri, Hirsh Jeffrey
机构信息
University of Tennessee Medical Center, Graduate School of Medicine, Knoxville, Tennessee.
Cardiology, University of Tennessee Medical Center, Knoxville, Tennessee.
出版信息
HeartRhythm Case Rep. 2020 Jan 28;6(5):268-271. doi: 10.1016/j.hrcr.2020.01.009. eCollection 2020 May.
Abstract
摘要
相似文献
1
Scared to death-A novel mutation in catecholaminergic polymorphic ventricular tachycardia.
HeartRhythm Case Rep. 2020 Jan 28;6(5):268-271. doi: 10.1016/j.hrcr.2020.01.009. eCollection 2020 May.
2
Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.一名患有睡眠和运动期间有症状的儿茶酚胺能多形性室性心动过速的青少年患者中一种新型兰尼碱受体2（RyR2）突变的描述：病例报告
J Med Case Rep. 2018 Oct 9;12(1):298. doi: 10.1186/s13256-018-1825-6.
3
Bidirectional ventricular tachycardia: a hallmark of catecholaminergic polymorphic ventricular tachycardia.双向性室性心动过速：儿茶酚胺能多形性室性心动过速的一个标志。
Indian Pacing Electrophysiol J. 2012 Mar;12(2):65-8. doi: 10.1016/s0972-6292(16)30481-8. Epub 2012 Apr 30.
4
A novel variant in RyR2 causes familiar catecholaminergic polymorphic ventricular tachycardia.兰尼碱受体2（RyR2）中的一种新型变异导致家族性儿茶酚胺能多形性室性心动过速。
Forensic Sci Int. 2017 Jan;270:173-177. doi: 10.1016/j.forsciint.2016.12.001. Epub 2016 Dec 9.
5
Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.氟卡尼治疗可抑制 CASQ2 相关儿茶酚胺敏感性多形性室性心动过速患者运动诱发的室性心律失常。
Heart Rhythm. 2013 Nov;10(11):1671-5. doi: 10.1016/j.hrthm.2013.08.011. Epub 2013 Aug 13.
6
A rare cause of sudden cardiac arrest: Catecholaminergic polymorphic ventricular tachycardia.心脏骤停的罕见原因：儿茶酚胺能多形性室性心动过速。
Turk Pediatri Ars. 2018 Jun 1;53(2):124-128. doi: 10.5152/TurkPediatriArs.2017.3899. eCollection 2018 Jun.
7
BASIC AND CLINICAL INSIGHTS IN CATECHOLAMINERGIC (FAMILIAL) POLYMORPHIC VENTRICULAR TACHYCARDIA.儿茶酚胺能（家族性）多形性室性心动过速的基础与临床见解
Rev Invest Clin. 2019;71(4):226-236. doi: 10.24875/RIC.19002939.
8
A Homozygous Mutation in a Japanese Patient with Catecholaminergic Polymorphic Ventricular Tachycardia.一名患儿茶酚胺能多形性室性心动过速的日本患者中的纯合突变
Case Rep Genet. 2019 Jan 8;2019:9056596. doi: 10.1155/2019/9056596. eCollection 2019.
9
Catecholaminergic polymorphic ventricular tachycardia in a child: a case report.一名儿童的儿茶酚胺能多形性室性心动过速：病例报告
Acta Paediatr. 2008 Jan;97(1):127-9. doi: 10.1111/j.1651-2227.2007.00575.x. Epub 2007 Dec 3.
10
Catecholaminergic polymorphic ventricular tachycardia found in an adolescent after a methylenedioxymethamphetamine and marijuana-induced cardiac arrest.青少年在亚甲二氧基甲基苯丙胺和大麻诱发心脏骤停后出现儿茶酚胺多形性室性心动过速。
Crit Care Med. 2012 Jul;40(7):2223-6. doi: 10.1097/CCM.0b013e318250a870.
本文引用的文献
1
Catecholaminergic polymorphic ventricular tachycardia patients with multiple genetic variants in the PACES CPVT Registry.儿茶酚胺多形性室性心动过速患者在 PACES CPVT 注册中心有多个基因突变。
PLoS One. 2018 Nov 7;13(11):e0205925. doi: 10.1371/journal.pone.0205925. eCollection 2018.
2
Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review.植入型心律转复除颤器在儿茶酚胺多形性室性心动过速中的应用：一项系统评价。
Heart Rhythm. 2018 Dec;15(12):1791-1799. doi: 10.1016/j.hrthm.2018.06.046. Epub 2018 Jul 3.
3
The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry.儿茶酚胺多形性室性心动过速的临床和遗传谱：来自国际多中心注册研究的结果。
Europace. 2018 Mar 1;20(3):541-547. doi: 10.1093/europace/euw389.
4
Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia.致心律失常性右室心肌病相关的心脏兰尼碱受体基因突变导致儿茶酚胺敏感性多形性室性心动过速的临床和分子特征。
Heart Rhythm. 2015 Jul;12(7):1636-43. doi: 10.1016/j.hrthm.2015.03.033. Epub 2015 Mar 23.
5
HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.遗传性原发性心律失常综合征患者诊断与管理的HRS/EHRA/APHRS专家共识声明：2013年5月由HRS、EHRA和APHRS认可，2013年6月由ACCF、AHA、PACES和AEPC认可。
Heart Rhythm. 2013 Dec;10(12):1932-63. doi: 10.1016/j.hrthm.2013.05.014. Epub 2013 Aug 30.
6
Catecholaminergic polymorphic ventricular tachycardia: A paradigm to understand mechanisms of arrhythmias associated to impaired Ca(2+) regulation.儿茶酚胺敏感性多形性室性心动过速：理解与钙调节受损相关心律失常机制的范例。
Heart Rhythm. 2009 Nov;6(11):1652-9. doi: 10.1016/j.hrthm.2009.06.033. Epub 2009 Jun 30.
7
Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.儿茶酚胺能多形性室性心动过速心律失常事件的发生率及危险因素
Circulation. 2009 May 12;119(18):2426-34. doi: 10.1161/CIRCULATIONAHA.108.829267. Epub 2009 Apr 27.
8
Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.儿茶酚胺能多形性室性心动过速的诊断与治疗
Heart Rhythm. 2007 May;4(5):675-8. doi: 10.1016/j.hrthm.2006.12.048. Epub 2007 Jan 7.
Zotero 插件